IgG1 Antibody Responses to Tumor Antigens Predict Outcomes in Immune Checkpoint Therapy
Here’s a breakdown of the facts from the provided text and figure captions, focusing on the key findings regarding IGHG1 and cancer survival:
key Findings:
* IGHG1 and immunotherapy Response: High expression of IGHG1 (an IgG1 gene) is associated with improved survival in patients with Non-Small Cell Lung Cancer (NSCLC) treated with anti-PD-L1 immunotherapy. This was observed across 26 trials (reference id=”ref-link-section-d2580866e2208″>26).
* No effect in Chemotherapy-Treated Cancers: IGHG1 expression does not appear to correlate with survival outcomes in cancers treated with chemotherapy. Specifically, no effect was seen in Lung Squamous Cell Carcinoma (LUSC) and Liver Hepatocellular Carcinoma (LIHC).
* figure 6 Details:
* 6a: Kaplan-Meier survival analysis shows the association between high IGHG1 expression and improved overall survival (OS) in Skin Cutaneous Melanoma (SKCM), in addition to NSCLC.
* 6b: Plasma IgG1 cells are major contributors to cell-cell interactions in responders.
* 6c & 6d: Cell-cell interactions are different between responders and non-responders, with plasma IgG1 cells and myeloid compartments being more engaged in responders.
* 6e & 6f: Trajectory analysis reveals differences in gene expression between responders and non-responders, highlighting genes like RRBP1, CXCR4, ERN1, and IGHG1.
In essence, the study suggests that the benefit of IGHG1 expression on survival is specifically linked to the use of immunotherapy, and not traditional chemotherapy. The figure details suggest that IGHG1 plays a role in immune cell interactions that contribute to a better response to immunotherapy.